Operates across three reported business areas: Pharmaceuticals, Agro, and Plastic polymer films, with consolidated FY26 revenue of Rs. 115.91 crore and a net profit of Rs. 0.39 crore. The June 2026 filings disclose a non-binding strategic cooperation and technology transfer agreement to set up a plastic film manufacturing project in the Kyrgyz Republic, covering technology transfer, machinery sourcing, government liaison, investment facilitation, skill development, import-export support, and financing assistance; no monetary consideration has been recorded and a joint venture is only contemplated later. The cost shape is unusual for a manufacturer: materials are shown as 0.0% of revenue, with employee cost at 0.4% and other operating expenses at 0.2% of revenue, suggesting the reported revenue is largely a pass-through or trading activity rather than in-house manufacturing. Operating cash flow on a standalone basis was negative Rs. 121.35 Lacs in FY26, even as the company moved from a loss of Rs. 69.51 Lacs in FY25 to a profit of Rs. 37.50 Lacs on a standalone revenue jump from Rs. 294.28 Lacs to Rs. 11,223.10 Lacs. The company is a micro-cap BSE-listed entity (paid-up equity Rs. 4 crore, net worth Rs. 4.02 crore) headquartered in Ahmedabad, with two promoters holding shares and no encumbrance declared on them. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceuticals, Agro, Plastic polymer films. Small, multi-segment micro-cap with a trading-style cost structure and a cross-border plastic film project in early, non-binding stage.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 10 | 18 | 28 | 7 | 116 |
| EBITDA (ex other income) | (0) | 1 | 1 | (0) | 1 |
| margin % | (0.8) | 3.7 | 3.8 | (4.9) | 0.6 |
| Owners' profit | 0 | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | 0.83 | 1.50 | 0.14 | 0.17 | 0.10 |
| ROE % · ROCE % | 9.5 · 12.1 | 14.6 · 20.5 | 11.8 · 15.1 | (17.0) · (4.3) | 9.0 · 15.7 |
| Debt / equity (x) | 0.79 | 1.95 | 1.11 | 2.18 | 2.34 |
| Cash from operations | 2 | (1) | 2 | (2) | (1) |
| Capex | 0 | 0 | (0) | (0) | (0) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 2 | 0 | 9 | 55 | 45 | 6 | 9 |
| Profit before tax | 0 | 0 | (1) | 0 | 1 | 0 | (0) | 0 |
| Net profit | 0 | 0 | (1) | 0 | 1 | 0 | (0) | 0 |
| EPS (₹) | 0.00 | 0.01 | 0.25 | 0.02 | 0.14 | 0.05 | 0.11 | 0.04 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · 44th AGM outcome: 9 items put to e-vote, results awaited | board shareholder meetings | low | — | — |
| 20 Aug 2026 · Notice of 44th AGM and e-voting info published in newspapers | compliance | minimal | — | — |
| 19 Aug 2026 · Notice of 44th AGM and Annual Report for FY 2025-26 | board shareholder meetings | medium | — | — |
| 19 Aug 2026 · 44th AGM notice on September 11, 2026 via video conference | board shareholder meetings | low | — | — |
| 17 Aug 2026 · Board approves FY26 reports, 44th AGM on Sep 4, seeks borrowing and related party approvals | board shareholder meetings | low | — | — |
| 8 Aug 2026 · Reg 32 deviation filing not applicable - no recent fund raises | compliance | minimal | — | — |
| 8 Aug 2026 · Vivanza Biosciences submits Q1 FY27 results newspaper clippings | compliance | minimal | — | — |
| 7 Aug 2026 · Vivanza Biosciences Q1 FY27 Results Revenue 914L PAT 14.51L | results | high | — | — |
| 7 Aug 2026 · Vivanza Biosciences Q1 FY27 results: PAT jumps to Rs 14.51 lakh | results | high | — | — |
| 7 Aug 2026 · Q1 FY27 Results: Profit jumps over 7x YoY on revenue growth | results | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 5.6 | 28.9 | 11 of 169 | 94% |
| P/B | 1.7 | 3.3 | 44 of 163 | 74% |
| ROCE | 10.4 | 10.8 | 95 of 183 | 48% |
| ROE | 9.1 | 10.4 | 96 of 171 | 44% |
| Debt / Equity | 2.3 | 0.1 | 168 of 171 | 2% |
| EBITDA margin | 3.2 | 17.5 | 147 of 165 | 11% |
| Revenue growth | 3.9 | 16.3 | 117 of 161 | 28% |
| Profit growth | 68.7 | 30.9 | 50 of 158 | 69% |
| Market cap | 8 | 839 | 176 of 182 | 3% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
